北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 血液科  > 期刊论文
学科主题: 临床医学
题名:
MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial
作者: Zhu, Hong-Hu1; Zhang, Xiao-Hui1; Qin, Ya-Zhen1; Liu, Dai-Hong1; Jiang, Hao1; Chen, Huan1; Jiang, Qian1; Xu, Lan-Ping1; Lu, Jin1; Han, Wei1; Bao, Li1; Wang, Yu1; Chen, Yu-Hong1; Wang, Jing-Zhi1; Wang, Feng-Rong1; Lai, Yue-Yun1; Chai, Jun-Yue2; Wang, Li-Ru3; Liu, Yan-Rong1; Liu, Kai-Yan1; Jiang, Bin1; Huang, Xiao-Jun1,4
刊名: BLOOD
发表日期: 2013-05-16
DOI: 10.1182/blood-2012-11-468348
卷: 121, 期:20, 页:4056-4062
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Hematology
研究领域[WOS]: Hematology
关键词[WOS]: ACUTE MYELOID-LEUKEMIA ; MINIMAL RESIDUAL DISEASE ; STEM-CELL TRANSPLANTATION ; PROGNOSTIC VALUE ; MARROW-TRANSPLANTATION ; AML1-ETO-POSITIVE AML ; KIT MUTATIONS ; GROUP-B ; RQ-PCR ; INV(16)
英文摘要:

We aimed to improve the outcome of t(8;21) acute myeloid leukemia (AML) in the first complete remission (CR1) by applying risk-directed therapy based on minimal residual disease (MRD) determined by RUNX1/RUNX1T1 transcript levels. Risk-directed therapy included recommending allogeneic hematopoietic stem cell transplantation (allo-HSCT) for high-risk patients and chemotherapy/autologous-HSCT (auto-HSCT) for low-risk patients. Among 116 eligible patients, MRD status after the second consolidation rather than induction or first consolidation could discriminate high-risk relapse patients (P = .001). Allo-HSCT could reduce relapse and improve survival compared with chemotherapy for high-risk patients (cumulative incidence of relapse [CIR]: 22.1% vs 78.9%, P < .0001; disease-free survival [DFS]: 61.7% vs 19.6%, P = .001), whereas chemotherapy/auto-HSCT achieved a low relapse rate (5.3%) and high DFS (94.7%) for low-risk patients. Multivariate analysis revealed that MRD status and treatment choice were independent prognostic factors for relapse, DFS, and OS. We concluded that MRD status after the second consolidation may be the best timing for treatment choice. MRD-directed risk stratification treatment may improve the outcome of t(8; 21) AML in CR1. This trial was registered at http://www.chictr.orgas #ChiCTR-OCH-12002406.

语种: 英语
所属项目编号: 81230013 ; Z111107067311070
项目资助者: National Natural Science Foundation of China ; Ministry of Health (China) ; Beijing Municipal Science and Technology Commission
WOS记录号: WOS:000321871900010
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/50961
Appears in Collections:北京大学第二临床医学院_血液科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China
2.Beijing 6 Hosp, Beijing, Peoples R China
3.Beijing Rehabil Hosp, Beijing, Peoples R China
4.Peking Univ, Inst Hematol, Peking Univ Peoples Hosp, Beijing 10044, Peoples R China

Recommended Citation:
Zhu, Hong-Hu,Zhang, Xiao-Hui,Qin, Ya-Zhen,et al. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial[J]. BLOOD,2013,121(20):4056-4062.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Zhu, Hong-Hu]'s Articles
[Zhang, Xiao-Hui]'s Articles
[Qin, Ya-Zhen]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Zhu, Hong-Hu]‘s Articles
[Zhang, Xiao-Hui]‘s Articles
[Qin, Ya-Zhen]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace